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Background: Psoriasis is a chronic hyperproliferative inflammatory skin disease, characterized by a
generalized redox imbalance. Anti-tumor necrosis factor (TNF)-α therapy is widely used for the treatment
of this disease, but its effect on blood redox status hasn’t been explored.
Objective: To investigate the effects of anti-TNF-α therapy on blood redox status in psoriatic patients.
Methods: Twenty-nine psoriatic patients (PSO) were divided into two groups: one remained untreated (NRT)
and to another the anti-TNF-α therapy was prescribed (TR). The levels of main oxidative stress markers and
total antioxidant capacity (TAC) in plasma, levels of total reactive oxygen species (ROS) production,
lipoperoxidation, TAC, glutathione content, and activity of NADPH oxidase in white blood cells (WBC) were
evaluated in PSO, in NTR and TR after 6 months of the study.
Results: Plasma levels of malondialdehyde (MDA) and protein carbonyl content (PCO), ROS production,
lipoperoxidation, and glutathione content in WBC were increased, while TAC in both plasma and WBC
was decreased in PSO with respect to controls. In the plasma of TR, levels of MDA and PCO were
significantly lower with respect to PSO and NTR. The activity of NADPH oxidase was significantly
increased in WBC of PSO and NTR but not in TR versus controls.
Discussion:Our results represent novel data about the redox status of WBC in psoriatic patients. A significant
redox-balancing effect of anti-TNF-α therapy, probably associated with the normalization of NADPH oxidase
activity in WBC, was demonstrated.
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Introduction
Psoriasis is an inflammatory skin disease, character-
ized by the appearance of itchy or sore patches of
thick, red skin with silvery scales. The etiology of the
disease is still unknown, but T lymphocytes, dendritic
cells, neutrophils, and macrophages are believed to
play a relevant part in its progression.1 In psoriasis,
these cells infiltrate the skin and release pro-inflamma-
tory cytokines (such as interleukin-6, inerferon-γ, and
TNF-α and O2
•−,2,3 perturbing the redox balance of
the skin and inducing the progression of inflam-
mation. Recent evidence suggests that the redox imbal-
ance found in blood and skin of the patients plays an
important role in the pathogenesis of psoriasis.3
Indeed, numerous studies revealed significantly
increased levels of oxidative stress markers such as
malondialdehyde (MDA), nitric oxide end pro-
ducts,3–6 and 8-OHdG (8-hydroxydeoxyguanosine)7
in the plasma of psoriatic patients. Likewise, decreased
total antioxidant capacity (TAC), vitamin A and E
levels, and decreased activity of the main antioxidant
enzymes (such as erythrocyte and serum superoxide
dismutase and catalase) were also found in the
plasma of these patients.3–6,8 Moreover, the ‘severity’
of plasma redox imbalance was found to be strongly
correlated with the Psoriasis Area and Severity Index
(PASI),4–8 which in turn correlates with the level of
inflammatory cytokines.8
The central role of TNF-α in the pathogenesis of
psoriasis has been demonstrated by the clinical
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efficacy of TNF-α antagonists. There are now five
TNF inhibitors available for the treatment of various
immune-mediated and inflammatory diseases9–13:
Infliximab (IFX), Adalimumab, and Golimumab are
full-length monoclonal antibodies; Etanercept is a
fusion protein of two TNFR2 receptor extracellular
domains and the Fc fragment of human immuno-
globulin 1 (IgG1); and Certolizumab is a humanized
Fab fragment conjugated to polyethylene glycol.14,15
While these drugs appear to have a similar effi-
cacy,14,16 the choice of one or another TNF inhibitor
is personalized for each psoriatic patient.17 It is impor-
tant to note that TNF-α also acts as a potent inducer
of ROS generation through impairment of mitochon-
drial biogenesis and activation of NADPH
oxidase.8,18–23 Taken together, these data allow us to
speculate that the immune system and the redox
system might in some way interact synergistically,
such that both mechanisms might be relevant in the
pathogenesis of psoriasis.
In this study, we aimed to analyze the effects of
anti-TNF treatment with IFX on the blood redox
status in psoriatic patients. Main oxidative stress
markers (MDA and protein carbonyl content (PCO))
and TAC in plasma were assessed. Particular attention
was paid to the evaluation of oxidative stress markers,
antioxidant capacity, and NADPH oxidase activity in
WBC obtained from treated and untreated patients.
The results of the current study show the presence of
redox imbalance in the blood of psoriatic patients
and suggest a possible relationship between TNF-α
and NADPH oxidase activity in WBC of psoriatic
patients.
Materials and methods
Patients
The study was approved by the Local Ethical
Community and carried out according to the
Helsinki Declaration. Analyses were carried out in
29 patients (20 females and 9 males) affected by mod-
erate psoriasis (PASI= 13± 1 SD; the group ‘PSO’)
with a mean age of 47± 8 SD years, and with a
mean duration of disease of 17 years (from 1 to 35
years). The demographic and clinical information for
each patient is summarized in Table 1. Eighteen non-
stressed healthy controls (10 females and 8 males),
matched for age and body mass index were also
enrolled in the study. No subjects involved in the
study followed any systemic therapy before the study
or had a history of any disease, e.g. diabetes mellitus
and atherosclerosis, which might affect the redox
status.
Table 1 Demographic and clinical data of patients involved in the study
Patients Age BMI Duration of the disease (years)
PASI
T = 0 (months) T = 6 (months)
TR M1 39 24 5 12 3
M3 40 26 3 12 4
M6 47 25 20 12 4
M8 40 27 15 12 3
F1 54 27 20 13 3
F4 47 24 20 12 4
F5 49 21 15 13 3
F9 48 25 25 12 2
F11 55 29 30 13 3
F15 48 20 10 12 4
F18 49 23 20 12 3
F19 35 22 3 14 4
F20 66 27 28 13 3
TR (Mean± SD) – 47± 8 25± 3 16± 9 13± 1 3± 1
NTR M9 34 21 1 13 12
F6 54 28 30 12 12
F7 46 24 21 12 11
F8 33 19 2 13 11
M7 41 25 4 13 12
F10 53 28 30 13 13
M4 45 23 12 13 12
F12 47 20 25 14 12
F13 55 24 20 14 12
F14 62 29 35 13 11
F2 56 25 20 13 12
F16 42 20 12 13 13
F17 39 18 5 13 11
F3 42 23 11 12 10
M2 42 25 8 13 12
M5 50 28 28 14 13
NTR (Mean± SD) – 48± 8 24± 3 17± 11 13± 1 12± 1
M, male; F, female; BMI, body mass index (kg/m2); PASI, Psoriasis Area and Severity Index; TR, psoriatic patients after 6 months of
anti-TNF-α therapy (n= 13); NTR, psoriatic patients after 6 month without any systematic treatment (n= 16).
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Redox status was analyzed in the blood of PSO and
Controls as described below. After that, the PSO group
was divided into two sub-groups: (1) was prescribed
the anti-TNF-α therapy via intravenous adminis-
tration of 5 mg/kg IFX every 8 weeks for 6 months
(‘treated’ psoriatic patients or ‘TR’); and (2) was not
prescribed any systemic treatment for the duration of
the study (‘untreated’ psoriatic patients or ‘NTR’).
After 6 months blood analysis was repeated and the
PASI again estimated in both TR and NTR groups
of patients.
Management of the blood samples
Ten milliliters of peripheral blood was collected in
EDTA tubes and treated to obtain: (a) WBC by BD
FACS Lysing Solution (BD Biosciences, San Jose,
Canada), following the manufacturer’s protocol, (b)
mononuclear cells (peripheral blood mononuclear
cell (PBMC)) using 1.077 g/ml Ficoll Hypaque sol-
ution (Sigma-Aldrich, Milan, Italy), again following
the manufacturer’s protocol, and (c) plasma by cen-
trifugation of whole blood at 800g for 10 minutes.
Plasma was analyzed at the earliest time points for
levels of thiobarbituric acid reactive substances
(TBARS) using a commercially available kit (Oxitek-
ZeptoMetrix Corporation, Buffalo, NY, USA), for
protein carbonylation (PCO) using a commercially
available Protein Carbonyl Fluorometric Assay Kit
(Cayman Chemical, USA), and for oxygen radical
antioxidant capacity (ORAC) as described below.
WBC were immediately subjected to flow cytometric
analysis (FACS) and for each of three populations,
namely granulocytes, monocytes, and lymphocytes
(Fig. 1, a), levels of intracellular ROS and lipoperoxi-
dation were estimated using the fluorescent dyes
H2DCF-DA and BODIPY 581/591 C11 (both from
Molecular Probes Invitrogen, Carlsbad, CA, USA),
respectively.24,25 Total cell lysates of WBC were pre-
pared for ORAC analysis and glutathione content
using the Glutathione Assay Kit (Cayman
Chemical). PBMC (1 × 106 cells/sample) were used
to determine NADPH oxidase activity by lucigenin-
based luminometric assay, as described below.
ORAC assay
The reaction was carried out in 96-well black micro-
plates (Nunc, Roskilde, Denmark), with trolox
(10–200 μM) used as a standard. The amount of
sample applied to each well was calculated as
follows: 12 μg of protein/sample for plasma and 4 μg
of protein/well for total cell lysates. The final assay
mixture (total volume= 200 μl) contained: 70 μl of
sample diluted in 75 mM phosphate buffer (pH 7.0)
and 100 μl of fluorescein reagent at final concentration
of 6 nM. After 10 minutes incubation in the dark at
37°C, 30 μl of pre-heated (at 37°C) AAPH (Sigma-
Aldrich Italy S.r.l.) solution (final concentration of
AAPH= 127 mM) was added to each well using a
multi-well channel pipette. Fluorescence was analyzed
using a fluorometric microplate reader (Fluoroskan
Ascent; Thermo Electron Corp., Vantaa, Finland) at
5 minutes intervals for 2 hours at excitation and emis-
sion wavelengths of 485 and 537 nm, respectively. All
assays were conducted in triplicate and at least two
independent tests were carried out for each sample.
The area under curve was calculated for each sample
by integrating the relative fluorescence curve.
Regression equations obtained from net value of
trolox were used to calculate the ORAC value for
each assay. Final ORAC values were expressed as
nmol trolox equivalent (TE) per ml (nmol TE/ml)
for plasma and μmol of TE per mg of protein (μmol
TE/mg) for WBC lysates.
NADPH oxidase activity luminometric assay
NADPH oxidase activity assay was performed on
intact PBMC using a Lumat LB 9507 single-tube
luminometer (Berthold Technologies, GmbH & Co,
Bad Wildbad, Germany). After washing with phos-
phate-buffered saline, 1 × 106 cells were resuspended
in 150 μl Krebs-HEPES buffer (99 mM NaCl,
4.7 mM KCl, 1.2 mM MgSO4, 1 mM KH2PO4,
1.9 mM CaCl2, 25 mM NaHCO3, 20 mM HEPES,
11.1 mM glucose, pH 7.44) and incubated for
10 minutes at 37°C and the blank value of lumines-
cence was determined. Following this, lucigenin was
added to the sample at a final concentration of
25 μM. Immediately after that a series of luminescence
readings taken at 1-minute intervals for 30 minutes at
37°C was performed. We used two controls for
NADPH oxidase activity: (1) by the 20th reading,
the curve of NADPH oxidase activity normally
Figure 1 NADPH oxidase activity in intact PBMC, measured
by lucigenin-based assay. PSO, psoriatic patients prior to
anti-TNF-α therapy (n = 29); NTR, psoriatic patients without
any systematic treatment after 6months (n= 16); TR; psoriatic
patients after 6 months of anti-TNF-alpha therapy (n= 13).
SOD, superoxide dismutase. *P< 0.05 as compared to
control; #P< 0.05 as compared to NTR.
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reached a plateau and SODwas added to the sample at
a final concentration of 450 U/ml and (2) pre-incu-
bation with diphenyleneiodonium chloride, DPI,
(20 μM) for 30 minutes at 37°C led triggered no
response upon lucigenin addition. NADPH oxidase
activity was expressed as relative units of fluorescence
(RUL)/s.
Statistical analysis
All data are expressed as means± SD. Comparisons
between different groups were carried out using one-
way analysis of variance followed by the Bonferroni
t-test. A P value <0.05 was accepted as statistically
significant.
Results
Redox status of plasma and WBC in PSO
(T= 0 months)
Levels of oxidative stress markers, TBARS and PCO,
were significantly increased and TAC significantly
decreased in the plasma of PSO with respect to
controls (Table 2). In WBC of PSO total ROS
content and lipoperoxidation levels were also signifi-
cantly higher than controls in all three populations
of cells, that is, granulocytes, monocytes, and lym-
phocytes (Table 3). In total, WBC lysates from PSO
TAC was substantially lower with respect to WBC
from controls. In PSO, total glutathione levels in
WBC were significantly decreased, and levels of the
oxidized form increased with respect to controls
(Table 3).
We hypothesized that NADPH oxidase might be
responsible for ROS overproduction in PBMC
from psoriatic patients. Indeed, the results of
NADPH oxidase activity measured in PBMC (a
fraction of WBC lacking granulocytes26) revealed
increased activity of the enzyme in PBMC from
PSO compared to controls (Fig. 1). Interestingly, fol-
lowing SOD addition to the sample, the residual
(NADPH oxidase) activity in PSO PBMC was not
significantly different from the one in control
PBMC.
Table 2 Redox markers in plasma of psoriatic patients and controls
Redox markers
Control
Psoriatic patients
T= 0 (months)
T= 6 (months)
PSO (n= 29) NTR (n= 16) TR (n= 13)
TBARS (nmol/mg) 0.13± 0.02 0.36± 0.07* 0.33± 0.06* 0.25± 0.05*#&
PCO (nmol/mg) 4.21± 0.11 8.50± 0.80* 8.23± 0.32* 6.71± 0.36*#&
TAC (nM TE/ml) 82.65± 7.90 62.34± 8.07* 63.64± 6.07* 62.81± 5.97*
PSO, psoriatic patients who were not receiving any systemic treatment for at least 6 months before the beginning of study; NTR,
psoriatic patients without any systematic treatment after 6 months (n= 16); TBARS, thiobarbituric acid reactive substances, markers
of lipid peroxidation; PCO, protein carbonyl content, markers of oxidative protein damage; TAC, total antioxidant capacity; TE, trolox
equivalent.
Errors are defined as mean± SD.
*P< 0.05 as compared to control.
#P< 0.05 as compared to PSO.
&P< 0.05 as compared to NTR.
Table 3 Redox markers and glutathione content in WBC of psoriatic patients and controls
Redox markers Control
Psoriatic patients
T = 0 (months)
T= 6 (months)
PSO (n= 29) NRT (n= 16) TR (n= 13)
TAC (μmol TE/mg) 6.41± 1.82 3.83± 0,73* 3.39± 1.42* 6.14± 0.08#&
GSH+GSSG (nmol/mg) 4.3± 1,15 2.99± 0,73* 2.95± 0,61* 2.41± 0,07*
GSSG/GSH 0.15± 0,02 0.62± 0,07* 0.64± 0,04* 0.36± 0,05*#&
DCF, RFU
Cranulocytes 851± 102 1411± 233* 1363± 201* 1200± 190*#&
Monocytes 949± 150 1189± 111* 1220± 115* 1000± 100*#&
Lymphocytes 442± 132 801± 98* 722± 164* 550± 100*#&
BODIPY, RFU
Cranulocytes 900± 98 1321± 168* 1266± 228* 1129± 127#&
Monocytes 550± 79 1030± 121* 993± 104* 773± 135#&
Lymphocytes 200± 23 297± 34* 302± 20* 272± 40#&
GSH, glutathione; GSSG, oxidised form of glutathione; GSH+GSSG, total glutathione content; GSSG/GSH, the redox glutathione
ratio; RFU, relative fluorescent units; DCF, intracellular ROS production marker; BODIPY, lipoperoxidation marker.
Errors are defined as mean± SD.
*P< 0.05 as compared to control.
#P< 0.05 as compared to PSO.
&P< 0.05 as compared to NTR.
Barygina et al. Redox status in blood of psoriatic patients
Redox Report 2013 VOL. 18 NO. 3103
Redox status of plasma and WBC in TR and NTR
(T= 6 months)
After 6 months, the PASI and redox status of plasma
and WBC was re-evaluated in both groups of psoriatic
patients (TR and NTR); significant differences in
levels of oxidative stress markers were found between
TR and NTR. PASI showed a significant clinical
improvement in TR and a slight decrease, albeit not
significant, in NTR in comparison to PSO (Table 1).
TBARS and PCO were still significantly increased
and TAC significantly decreased in both TR and
NTR with respect to controls. However, levels of
TBARS and PCO in TR were significantly lower
than in NTR and PSO. Plasma TAC was not signifi-
cantly different in TR compared to NTR.
Assessment of oxidative stress markers in WBC
revealed tendencies similar to those observed for
plasma. The total ROS content in WBC was signifi-
cantly increased in both TR and NTR with respect
to controls in all three populations of WBC
(Table 3). However, levels of ROS production in
WBC from TR were lower with respect to WBC
from NTR. Interestingly, levels of lipid peroxidation
were not significantly different between TR and con-
trols, but significantly lower in TR compared to
NTR. TAC in WBC from NTR was substantially
lower than that in WBC of TR and controls. In con-
trast, no significant difference was found between
WBC TAC from TR and controls. A significant
decrease in total glutathione levels in WBC from
both NTR and TR, with respect to controls, was still
observed. Subsequently, a significant increase in oxi-
dized/reduced glutathione ratio (GSSG/GSH) was
observed in both TR and NTR compared to controls;
however, the GSSG/GSH ratio was significantly lower
in TR with respect to NTR (Table 3).
After 6 months NADPH oxidase activity showed
no significant change in NTR with respect to PSO.
Although, NADPH oxidase activity of PBMC from
the TR group was significantly decreased in compari-
son with PSO and NTR, it was still significantly higher
than the one of control PBMC. Following SOD treat-
ment the residual (NADPH oxidase) activity in NTR
and TR PBMC decreased. These values were not
significantly different from the residual NADPH
oxidase activity of control PBMC.
Discussion
Psoriasis is characterized by generalized oxidative
stress and by augmented levels of TNF-α, a well-
known inducer of ROS generation in non-phagocytic
cells. Chronic inflammatory processes associated
with redox imbalance in patients’ skin and blood can
frequently lead to premature atherosclerosis in psoria-
tic patients.17,27
IFX, a chimeric monoclonal anti-TNF-α antibody,
is frequently used for treatment of psoriasis.28–30
While biological agents have demonstrated efficacy
in patients with psoriasis and are generally considered
safe and well tolerated, rare but serious safety issues
(such as demyelination, infection, tuberculosis, malig-
nancy, lymphoma, cardiovascular outcomes, and
hepatitis) have been observed.31–35 Attention to
specific aspects of patient management (e.g. pre-
screening requirements, symptoms to watch for, appro-
priate treatment and referrals) is required to mitigate
the risk.36
A beneficial antioxidant effect of IFX treatment has
already been shown for the skin, plasma, and erythro-
cytes,37,38 but no data about its effect on WBC, which
play a prominent role in the immune profile of psoria-
sis, are present in the literature. In this study, we
assessed the effect of IFX therapy on plasma and
WBC redox status in psoriatic patients.
The results of our study confirm the presence of a
redox imbalance in the plasma of psoriatic patients.
In particular, we found significantly increased levels
of oxidative stress markers and decreased antioxidant
capacity in psoriatic patients with respect to controls.
Notably, levels of oxidative stress markers decreased
significantly after treatment with IFX; this finding
suggests a role for TNF-α in triggering ROS gener-
ation in psoriasis and that anti-TNF-α therapy signifi-
cantly reduces oxidative stress in the plasma of
affected patients. In contrast, antioxidant capacity
did not differ significantly in treated and untreated
patients, suggesting persistent antioxidant depletion
in the plasma of patients following IFX therapy.
Indeed, several recent publications suggest that anti-
TNF-α therapy could lead to a decrease in TAC
levels.38 In our case, treatment with IFX did not
affect TAC levels in the plasma of psoriatic patients.
Conversely, a significant increase in TAC was
observed in WBC following IFX therapy with
respect to NTR and PSO. This may be partly due to
the increase in reduced GSH with respect to the oxi-
dized GSSG form. The redox GSSG/GSH ratio was
much higher in untreated patients with respect to
treated patients and controls; IFX treatment signifi-
cantly decreased this ratio, which agrees with the find-
ings of other authors who reported upregulation of
glutathione-S-transferase and glutathione peroxidase
following anti-TNF-α therapy.37,38
Increased TAC in WBC from treated with respect to
untreated patients can be explained by the reduced
consumption of low-molecular-weight antioxidants.
Indeed, we have shown for the first time that ROS pro-
duction in WBC of treated patients was significantly
lower with respect to levels in untreated individuals,
which proves that anti-TNF-α therapy has a redox bal-
ancing effect.
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The results of our work reveal an upregulation of
NADPH oxidase activity in PBMC from untreated
patients. However, such incrimination of NADPH
oxidase activity was not observed in PBMC from
patients treated with IFX. This could partly explain
the IFX-induced decrease in ROS production in
PBMC of psoriatic patients. These findings agree
with those reported by other authors, who showed
that activity of NADPH oxidase can be regulated by
TNF-α.8,18–23
Indeed, a pronounced morphological change and
increase in ROS production in mitochondria following
TNF-α treatment has recently been shown in insulin-
resistant 3T3-L1 adipocytes.19 In another study,
human aortic smooth muscle cells and embryonic
kidney cells treated with TNF-α displayed increased
superoxide production, due to upregulated expression
of NOX4 and NOX2 isoforms of NADPH oxidase,
respectively.20 Yoshida and Tsunawaki21 demon-
strated that, following TNF-α stimulation, coronary
artery endothelial cells also show enhanced ROS-
generating activity via induction of NADPH oxidase
isoforms Nox2 and Nox4A. TNF-α has been also
shown to activate Nox1 NADPH oxidase in mouse
fibroblasts when cells undergo necrosis.22 Finally, an
in vitro study carried out by Cangemi et al.,23 which
was carried out in platelets from a subgroup of heart
failure patients, showed that TNF-α (at concentrations
commonly found in the peripheral circulation of heart
failure patients) activates platelet NOX2. Thus, TNF-
α increases ROS production and extracellular levels of
NOX2.
In summary, we have for the first time shown a
crucial redox imbalance in the WBC of psoriatic
patients. Moreover, we provide evidence that
NADPH oxidase might represent a leading source of
ROS overproduction in WBC from psoriatic patients,
although additional experiments should be performed
to support our observation. Finally, IFX therapy dis-
played a significant redox balancing effect, which
was associated with the modulation of NADPH
oxidase activity. Taken together, our results suggest
that the redox status of the blood is sensitive to treat-
ment with IFX; this allows us to propose the assess-
ment of blood redox status as a relevant tool to
control the progression of psoriasis and to estimate
the effectiveness of anti-TNF-α therapy.
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